Navigation Links
Resverlogix RVX-208 Second Clinical Trial Demonstrates Success on Key Reverse Cholesterol Transport Markers
Date:9/30/2009

ded our original expectation for enhancing ApoA-l production in humans," stated Donald J. McCaffrey, President and CEO of Resverlogix. "We know that the enhancement of ApoA-l and key RCT particles in the body is widely recognized by international experts as the necessary markers to potentially impact atherosclerosis regression. Hence, we have achieved another critically important clinical milestone for our Company," noted McCaffrey.

The Phase 1b/2a trial was a double blind safety and tolerance study which investigated the pharmacokinetics and also early pharmacodynamics effects of RVX-208. A total of 72 subjects enrolled in the trial. The study had three arms, a low dose arm with 24 subjects, a dose-escalation arm with 24 subjects, and a third high dose arm with 24 subjects. This trial also examined early markers for reverse cholesterol transport such as ApoA-l, HDL-c, pre-beta HDL and alpha HDL subparticles. Approximately half of the subjects had low levels of baseline HDL cholesterol.

Highlights from the study are as follows:

    -   The primary endpoint, plasma ApoA-I increase compared to placebo,
        achieved a range in all subjects of 5.1% - 10.4% in all doses at days
        8 and 28 respectively.
    -   At the lowest dose of 1mg/kg b.i.d. in subjects with low levels of
        HDL-c, plasma ApoA-l increases reached statistical significance of
        5.7% (p(less than)0.05) at day 8 and 7.8% (p(less than)0.05) at
        day 28.
    -   A critical RCT functionality marker, alpha-1 HDL particles,
        illustrated highly statistical significance with an increase of
        46.7% (p(less than)0.004), in all subjects and
        57.2% (p(less than)0.02) in the low dose arm over placebo at day 28.
    -   Pharmacokinetic parameters of RVX-208 were dose dependant with oral
        administration.
    -   RVX-208 was shown to be compatible with simvastatin (40mg).
    -   Seventy out of seventy two subjects completed the tria
'/>"/>
Resverlogix Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Resverlogix Phase 1b/2a Study Meets Primary Endpoint
2. Resverlogixs Success in Inflammation Program Results in 2 Patents Filed
3. Resverlogix Provides Quarterly Update
4. Resverlogix Board of Directors Update
5. Resverlogix Advances to Second Arm of Phase 1b/2a Clinical Trial
6. Resverlogix Announces Closing of Debt Redemption
7. Resverlogix Eliminates Sixty Percent of Remaining Debt
8. Resverlogix Issues a Management Statement
9. Resverlogix Board of Directors Update
10. Resverlogix Notice of Conference Call & Webcast
11. Jan Gray Joins Resverlogix Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... MA (PRWEB) October 30, 2014 ... and collaboration provider, offers Office 365 end users ... into a complete phone system by adding voice ... 365 (O365) includes Lync Online, a communication tool ... Lync calls. With hosted voice, O365 becomes a ...
(Date:10/30/2014)... (PRWEB) October 30, 2014 James Sherley says ... in adult tissue stem cell technology since his days as ... in Philadelphia in the late 1990’s. Sherley founded the ... The company holds all the intellectual property developed in Sherley’s ... at the Massachusetts Institute of Technology (MIT), and more recently ...
(Date:10/30/2014)... NY (PRWEB) October 30, 2014 Whitehouse ... for its ICH Stability Testing and Package Test Capacity. ... investment centers on a dramatic increase in environmental chamber ... of stability, storage and aging samples to be securely ... of this major capital expenditure has already taken place ...
(Date:10/30/2014)... October 30, 2014 Grace Century portfolio project, ... A. Manganello, Chairman of the Board, to the National ... The appointment was made by the Ministry of Health on ... 2014. , More than a year after Bahamian ... , Prime Minister Perry Christie said the government has completed ...
Breaking Biology Technology:SoundConnect Launches Voice Enablement and Hybrid Audio Conferencing for Office 365 2SoundConnect Launches Voice Enablement and Hybrid Audio Conferencing for Office 365 3Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 2Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 3Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 4Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 2Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 3Grace Century’s Stem Cell Biobank Project Announces Chairman’s Appointment to National Stem Cell Ethics Committee of The Bahamas 2Grace Century’s Stem Cell Biobank Project Announces Chairman’s Appointment to National Stem Cell Ethics Committee of The Bahamas 3
... ... ... ... ...
... ... ... ... ...
... ... ... ... ...
Cached Biology Technology:VIVUS to Present at Two Upcoming Investor Conferences 2VIVUS to Present at Two Upcoming Investor Conferences 3Foamix Ltd. and Therapeutics Inc. Enter Into Joint Venture to Develop New Prescription Foams for Inflammatory Skin Diseases - Will Target Over 20 Million Psoriasis and Atopic Dermatitis Patients 2Foamix Ltd. and Therapeutics Inc. Enter Into Joint Venture to Develop New Prescription Foams for Inflammatory Skin Diseases - Will Target Over 20 Million Psoriasis and Atopic Dermatitis Patients 3Foamix Ltd. and Therapeutics Inc. Enter Into Joint Venture to Develop New Prescription Foams for Inflammatory Skin Diseases - Will Target Over 20 Million Psoriasis and Atopic Dermatitis Patients 4Foamix Ltd. and Therapeutics Inc. Enter Into Joint Venture to Develop New Prescription Foams for Inflammatory Skin Diseases - Will Target Over 20 Million Psoriasis and Atopic Dermatitis Patients 5Foamix Ltd. and Therapeutics Inc. Enter Into Joint Venture to Develop New Prescription Foams for Inflammatory Skin Diseases - Will Target Over 20 Million Psoriasis and Atopic Dermatitis Patients 6Foamix Ltd. and Therapeutics Inc. Enter Into Joint Venture to Develop New Prescription Foams for Inflammatory Skin Diseases - Will Target Over 20 Million Psoriasis and Atopic Dermatitis Patients 7Repligen Announces Acquisition of Chromatography Technology Platform 2Repligen Announces Acquisition of Chromatography Technology Platform 3Repligen Announces Acquisition of Chromatography Technology Platform 4
(Date:10/29/2014)... New research presented at the Society for ... TX showed for the first time that it ... using a readily available nutritional supplement, AHCC. ... Judith A. Smith, Pharm.D., associate professor in the ... The University of Texas Health Science Center at ...
(Date:10/29/2014)... their food, but they also need protection from its harmful ... of molecules in plants that shields them from sun damage. ... American Chemical Society , one team reports on the mechanics ... and colleagues at Purdue University note that the harsh ultraviolet ... to plant DNA and, as a result, hinder plant growth. ...
(Date:10/29/2014)... City on September 19, 2014, leading geneticist and humanitarian ... Genome Sciences and Medicine at the University of Washington ... Tel Aviv University, was awarded the 2014 Lasker-Koshland Special ... her honorary degree from TAU, Prof. King was the ... and for the past 18 years she has been ...
Breaking Biology News(10 mins):HPV infections in women eradicated by AHCC, Japanese mushroom extract 2Geneticist and humanitarian: Prof. Mary-Claire King receives Lasker Award 2
... Patients who are fed more calories while in intensive ... less of their daily-prescribed calories, according to a recent ... database in the world. "Our finding is significant ... in the area of critical care nutrition that have ...
... down weight gain and serve as another tool in the ... Obese mice that were fed a compound found in green ... slowly than a control group of mice that did not ... of food science in agricultural sciences. "In this experiment, ...
... new report by researchers from the Smithsonian Tropical ... identifies gaps in forest monitoring and ways to ... of greenhouse gas emission reductions from activities aimed ... proposal to Reduce Emissions from Deforestation and Forest ...
Cached Biology News:Green tea helps mice keep off extra pounds 2Panama REDD: Getting what you pay for 2
Polyclonal Antibody to CRTR-1...
Recognizes NSCL1. The molecular weight of the protein is 14,616 Daltons....
Mouse monoclonal [3G131] to Desmoglein 1 ( Abpromise for all tested applications). entrezGeneID: 1828 SwissProtID: Q02413...
Mouse monoclonal [2D7/1] to E.coli LPS ( Abpromise for all tested applications). Antigen: Tissue / cell preparation: Escherichia coli J5 cells....
Biology Products: